Severe Prurigo Nodularis

ORLANDO — Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the American Academy of Dermatology Annual Meeting.

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo nodularis in the European Union, Galderma announced in a press release.

Nemolizumab monotherapy improved the signs and symptoms of prurigo nodularis, according to new data published in JAMA Dermatology.

For patients using nemolizumab to treat prurigo nodularis, withdrawing medication led to a greater risk for relapse, according to a study presented at the European Academy of Dermatology and Venereology meeting.

The FDA approved Nemluvio in the form of a prefilled pen for subcutaneous injection for the treatment of prurigo nodularis in adults, Galderma announced in a press release.

Nemolizumab doses of 30 mg and 60 mg with topical corticosteroid treatment yielded positive results in adolescent patients with prurigo nodularis, according to a study.

A new study found that the Worst Itch Numeric Rating Scale is a valid and reliable instrument to capture itch data of patients with prurigo nodularis.

Abrocitinib may be an effective and well-tolerated treatment for adults with prurigo nodularis and chronic pruritus of unknown origins, according to a study.

SAN DIEGO — In this Healio video perspective, Martin Metz, MD, discusses the results from a randomized, double-blind, placebo-controlled study of the Janus kinase inhibitor povorcitinib for the treatment of prurigo nodularis.